Wordt geladen...
Impact of four times daily dosing of oral treprostinil on tolerability and daily dose achieved in pulmonary hypertension
Oral treprostinil (TRE) is a prostacylin that is approved for the treatment of patients with pulmonary arterial hypertension (PAH). Dosing is approved for two or three times daily (t.i.d.); however, adverse effects, including gastrointestinal-related symptoms, may limit the ability to reach optimal...
Bewaard in:
| Gepubliceerd in: | Pulm Circ |
|---|---|
| Hoofdauteurs: | , , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
SAGE Publications
2017
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5731722/ https://ncbi.nlm.nih.gov/pubmed/29199910 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2045893217744512 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|